Form 4: Castle Biosciences CEO Derek Maetzold Sells Shares Under 10b5-1 Plan

Derek Maetzold, CEO of Castle Biosciences, sold shares of common stock on April 21, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 21, 2025, Derek J Maetzold, the President and CEO of Castle Biosciences, sold shares of the company's common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2024.
• Maetzold sold 1,236 shares directly at a price of $21.518 per share.
• Additionally, sales were made from several trusts for which Maetzold serves as trustee, including The Maetzold Descendants 2020 Trust (2,017 shares), Derek Maetzold 2020 Irrevocable Trust (1,731 shares), and several Maetzold 2018 Remainder Trusts (165 shares each).
• The weighted-average sale price was $21.518, with individual transactions ranging from $21.325 to $21.710.
• Following these transactions, Maetzold directly owns 74,627 shares and indirectly owns shares through various trusts, including DJM Grantor Retained Annuity Trust No. 5 (122,866 shares) and DJM Grantor Retained Annuity Trust No. 6 (26,134 shares).

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock sales by an insider. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although it is likely to be minimal given that it was conducted under a pre-arranged trading plan.

Key Dates

Keywords

Castle Biosciences, Derek Maetzold, stock sale, Form 4, Rule 10b5-1, insider trading, CSTL